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ABSTRACT:
Cyclic AMP (cAMP) regulates a number of cellular processes and modulates cell 
death induction. cAMP levels are altered upon stimulation of specific G-protein-coupled 
receptors inhibiting or activating adenylyl cyclases. Opioid receptor stimulation can 
activate inhibitory Gi-proteins which in turn block adenylyl cyclase activity reducing 
cAMP. Opioids such as D,L-methadone induce cell death in leukemia cells. However, 
the mechanism how opioids trigger apoptosis and activate caspases in leukemia cells 
is not understood. In this study, we demonstrate that downregulation of cAMP induced 
by opioid receptor activation using the opioid D,L-methadone kills and sensitizes 
leukemia cells for doxorubicin treatment. Enhancing cAMP levels by blocking opioid-
receptor signaling strongly reduced D,L-methadone-induced apoptosis, caspase 
activation and doxorubicin-sensitivity. Induction of cell death in leukemia cells by 
activation of opioid receptors using the opioid D,L-methadone depends on critical 
levels of opioid receptor expression on the cell surface. Doxorubicin increased opioid 
receptor expression in leukemia cells. In addition, the opioid D,L-methadone increased 
doxorubicin uptake and decreased doxorubicin efflux in leukemia cells, suggesting 
that the opioid D,L-methadone as well as doxorubicin mutually increase their cytotoxic 
potential. Furthermore, we found that opioid receptor activation using D,L-methadone 
alone or in addition to doxorubicin inhibits tumor growth significantly in vivo. These 
results demonstrate that opioid receptor activation via triggering the downregulation 
of cAMP induces apoptosis, activates caspases and sensitizes leukemia cells for 
doxorubicin treatment. Hence, opioid receptor activation seems to be a promising 
strategy to improve anticancer therapies.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the 
most frequent malignant disease in children but affects 
adolescents as well [1]. The intensification of treatment 
regimens and advances in supportive care, improved 
the survival rates of childhood ALL to 80%, whereas in 
adults the overall survival rate remains at approximately 
40% [2, 3]. Unfortunately, patients suffering from relapse 
have a poor outcome [4] which is mainly determined by 
the response to chemotherapy, involving a number of 
deregulated pathways like differentiation, survival and 
apoptosis [3, 5-7].
The main goal in chemotherapies is the concerted 
destruction of cells via apoptosis [8, 9]. Apoptosis can be 
mediated via the external death receptor/ligand pathway 
or the intrinsic pathway involving caspases [8-10]. Pro-
apoptotic proteins like Bax and anti-apoptotic proteins 
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(Bcl-2, Bcl-xL, XIAP) frequently involved in malignancies 
and treatment resistances regulate apoptosis induction [7, 
11-14].
Previous studies showed that the second messenger 
cyclic AMP (cAMP) inhibits doxorubicin as well as DNA-
damage-induced apoptosis [15, 16]. cAMP regulates a 
number of cellular processes. The production of cAMP 
is either increased or decreased upon stimulation of 
G-protein-coupled receptors which activate or inhibit 
adenylyl cyclases. cAMP is responsible for a multitude of 
actions like ion channel regulation and kinase activation 
[17-19]. Furthermore, cAMP can either stimulate or inhibit 
programmed cell death [20]. 
Methadone is a full-opioid agonist used as 
substitution for heroin or other opiates but also as long-
lasting analgesic in cancer pain [21]. Opioid receptor 
activation initiates a cascade of events resulting in a 
diversity of biological effects like analgesis, sedation 
but also effects on cell survival and proliferation can be 
observed [22-25]. Opioid receptor stimulation can activate 
inhibitory Gi-proteins which in turn block adenylyl 
cyclase activity reducing cAMP [17]. 
The opioid D,L-methadone induces apoptosis 
in human T-lymphoblastic and myeloid leukemia cell 
lines and overcomes chemoresistance in leukemia cells 
without affecting healthy lymphocytes [25]. Singh et 
al found an effective synergism in cell death induction 
using D,L-methadone in addition to an anti-Bcl-2-agent 
[23]. Furthermore, D,L-methadone strongly inhibits 
proliferation of leukemia and human lung cancer cell lines 
[22, 25-27].  
In this study, we found that opioid receptor 
activation induces cell death sensitization of leukemia 
cells ex vivo and in vivo. Our work provides evidence 
that the downregulation of cAMP induced by opioid 
receptor triggering induces apoptosis, activates caspases 
and sensitizes leukemia cells for doxorubicin treatment. 
In addition, we demonstrate that the opioid D,L-
methadone-induced cell death depends on critical levels 
of opioid receptor expression which can be increased 
by doxorubicin. Additionally, D,L-methadone increases 
doxorubicin influx and hampers its efflux in leukemia 
cells.
RESULTS
D,L-Methadone induces cell death in xenograft-
derived ALL cells depending on opioid receptor 
expression
The opioid D,L-methadone induces cell death 
in different leukemia cell lines [25]. To test the role of 
opioid receptor triggering in cell death induction and 
the clinical relevance of D,L-methadone in treatment 
of leukemia, we analyzed the anti-cancer effect of D,L-
methadone in different xenograft-derived ALL cells. The 
xenografts were originally established from patients with 
T-cell (ALL-SCID6, ALL-SCID3), B-cell (ALL-SCID7) 
[28] and B-cell precursor (BCP, pre-B-ALL-SCID) acute 
leukemia. First, we measured opioid-receptor expression 
on xenograft-derived ALL cells. ALL-SCID6, ALL-
SCID3, and ALL-SCID7 leukemia cells displayed high 
amounts of opioid-receptors whereas the pre-B-ALL-
SCID leukemia cells expressed only moderate levels of 
opioid-receptors (Figure 1A). To analyze if cell death 
induction using D,L-methadone depends on the levels 
of opioid receptor expression, we treated the xenograft-
derived ALL cells with different concentrations of D,L-
methadone (Figure 1B). We used therapeutic plasma 
concentrations of D,L-methadone (≤ 3µg/mL) and 
included 10µg/mL D,L-methadone, because levels of 
D,L-methadone in lymphatic tissue and marrow might 
be higher [23]. Therapeutic plasma concentrations of 
D,L-methadone (≤ 3µg/mL) induced a strong cell death 
in xenograft-derived ALL cells (Figure 1B) expressing 
high amounts of opioid-receptors (Figure 1A). In 
contrast, the xenograft-derived-BCP-ALL cells (pre-B-
ALL-SCID) expressing moderate opioid-receptor levels 
(Figure 1A) could only be slightly killed with therapeutic 
concentrations of D,L-methadone (Figure 1B). Therefore, 
apoptosis induction by D,L-methadone seems to depend 
on the level of opioid-receptor expression.
D,L-methadone sensitizes ALL-cells for 
doxorubicin-induced cell death and caspase 
activation 
In analogous studies, we tested the cytotoxic 
potential of D,L-methadone on BCP-ALL cell lines 
(Tanoue, Reh, Nalm6) expressing opioid-receptors in a 
moderate level on their cell surface (Figure 2A). These 
BCP-ALL cell lines could only be killed slightly by 
D,L-methadone (Figure 2B) as observed for xenograft-
derived-BCP-ALL cells (pre-B-ALL-SCID) (Figure 1B). 
As different substances can act synergistically, we treated 
Tanoue, Reh, Nalm6, and xenograft-derived-BCP-ALL 
cells (pre-B-ALL-SCID) with different concentrations of 
D,L-methadone and doxorubicin alone or in combination 
with each other (Figure 2 B, 2C and 2D). We observed 
that the combination treatment strongly killed the BCP-
ALL cell lines (Figure 2B) and strongly reduced survival 
of BCP-ALL cell lines markedly (Figure 2C). The 
combination treatment also strongly killed xenograft-
derived-BCP-ALL cells (pre-B-ALL-SCID) (Figure 2D). 
To analyze the molecular pathways of cell killing 
in more detail and to find out how the combination 
treatment with D,L-methadone and doxorubicin induced 
apoptosis, we analyzed which apoptotic effector molecules 
are activated in BCP-ALL cells upon this combination 
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treatment compared to cells treated with D,L-methadone 
or doxorubicin alone. 120h after treating the BCP-ALL 
cell line Tanoue with D,L-methadone in addition to 
doxorubicin, we observed the activation of the caspase 
cascade in BCP-ALL cells. We found a strong activation 
of caspase-3 and caspase-9 and cleavage of the prototype 
substrate of caspase-3, PARP (Figure 3A). 
The role of the caspase cascade in apoptosis 
induction was further investigated with the broad-spectrum 
inhibitor of caspases zVAD.fmk. zVAD.fmk strongly 
decreased cell death after combination treatment with D,L-
methadone and doxorubicin in BCP-ALL cells (Figure 3B) 
underlining the dependence on caspase activation. 
The apoptotic machinery is tightly controlled by 
anti-apoptotic factors like XIAP and Bcl-xL [11, 12] which 
we found to be strongly downregulated in BCP-ALL cells 
treated with D,L-methadone in addition to doxorubicin 
(Figure 3C). These results indicate that the combination 
of D,L-methadone and doxorubicin sensitizes BCP-ALL 
cells for apoptosis via the activation of caspases and 
downregulation of XIAP and Bcl-xL.
D,L-methadone enhances doxorubicin-uptake and 
inhibits doxorubicin-efflux whereas doxorubicin 
induces opioid-receptor expression
The efficiency of cell death induction and activation 
of effector molecules in apoptosis pathways after treating 
leukemia cells with D,L-methadone seems to depend on 
the amount of opioid-receptors displayed on the cell`s 
surface. Combination treatment with D,L-methadone and 
doxorubicin kills leukemia cells with moderate opioid 
receptor expression, which could only be killed slightly by 
D,L-methadone or doxorubicin alone. Chemotherapeutics 
enhance the expression of receptors like CD95 in leukemia 
cells [29]. To analyze whether doxorubicin might influence 
the opioid-receptor expression, we treated the BCP-ALL 
cell line Tanoue with doxorubicin for 96h. Afterwards, the 
relative amount of opioid-receptors compared to untreated 
cells was measured by flow cytometry. We found that 
doxorubicin strongly increased opioid-receptor expression 
(Figure 4A) suggesting that D,L-methadone can bind in 
higher amounts to cells co-treated with doxorubicin. 
Opioids as well as doxorubicin are substrates 
Figure 1: D,L-Methadone kills ALL cells ex vivo depending on critical levels of opioid receptor expression. (a) Human 
ALL-SCID6, ALL-SCID3, ALL-SCID7, and pre-B-ALL-SCID leukemia cells derived from xenografted mice display different levels of 
opioid-receptors on their cell surface. The cells were stained with naloxone-fluoresceine measuring opioid-receptor expression (OR, thick 
black curve) and analyzed by flow cytometry. Controls (Co, unstained cells) are exhibited as thin black curves. (b) ALL-SCID6, ALL-
SCID3, ALL-SCID7, and pre-B-ALL-SCID leukemia cells were treated with different concentrations of D,L-methadone (as indicated). 
After 24h (white columns) and 48h (black columns), the fractions of apoptotic cells were measured by FSC/SSC-analysis. The percentage 
of specific apoptosis was calculated as follows: 100 x [experimental dead cells (%) - spontaneous dead cells in medium (%)] / [100% - 
spontaneous dead cells in medium(%)]. Columns, mean of triplicates; bars, SD<10%.
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Figure 2: Combination treatment with D,L-methadone and doxorubicin induces apoptosis in ALL cells expressing 
moderate amounts of opioid receptors. (a) Different BCP-ALL cell lines (Tanoue, Nalm6 and Reh) express a moderate number 
of opioid-receptors on their cell surface. Tanoue, Nalm6 and Reh were stained with naloxone-fluoresceine measuring opioid-receptor 
expression (OR, thick black curve) and analyzed by flow cytometry. Controls (Co, unstained cells) are exhibited as thin black curves. (b) 
BCP-ALL cell lines (Tanoue, Nalm6 and Reh) were treated with different concentrations of D,L-methadone alone (- Doxo, white columns), 
with doxorubicin alone or with D,L-methadone in addition to doxorubicin (+ Doxo, black columns). For the cell line Tanoue, we used 
doxorubicin in a concentration of 0.06µg/mL, for Nalm6 and Reh in a concentration of 0.01µg/mL. 120h after stimulation, the percentages 
of apoptotic cells were measured by FSC/SSC-analysis. (C) BCP-ALL cell lines (Tanoue, Nalm6 and Reh) were treated with different 
concentrations of D,L-methadone alone (- Doxo, triangle), with doxorubicin alone or with D,L-methadone in addition to doxorubicin (+ 
Doxo, square). For the cell line Tanoue, we used doxorubicin in a concentration of 0.06µg/mL, for Nalm6 and Reh in a concentration of 
0.01µg/mL. 120h after stimulation, the percentages of surviving cells were measured by FSC/SSC-analysis (D). D,L-Methadone strongly 
enhances doxorubicin sensitivity of xenograft-derived-BCP-ALL-cells ex vivo. Xenograft-derived-BCP-ALL cells (pre-B-ALL-SCID) 
were treated with different concentrations of D,L-methadone (as indicated) alone (- Doxo, white columns), with 0.01µg/mL doxorubicin 
alone or with D,L-methadone in addition to doxorubicin (+ Doxo, black columns). 48h after stimulation, the percentages of apoptotic cells 
were measured by FSC/SSC-analysis. The percentage of specific apoptosis was calculated as described in Figure 1B. Columns, mean of 
triplicates; bars, SD<10%.
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of the in multi-drug resistances-involved efflux pump 
P-glycoprotein (P-gp). Furthermore, D,L-methadone 
is known to inhibit P-gp [30-33]. To analyze whether 
D,L-methadone might influence the uptake and/or efflux 
of doxorubicin in leukemia cells, the BCP-ALL cell 
line Tanoue was incubated for different intervals with 
doxorubicin alone or with a combination of doxorubicin 
and D,L-methadone. After 4h, 8h, 24h (maximum uptake), 
we observed an enhanced doxorubicin concentration in the 
cells co-incubated with doxorubicin and D,L-methadone 
(Figure 4B). 24h after maximum uptake of doxorubicin, 
doxorubicin was removed from the supernatant and 
fresh medium was added without doxorubicin and D,L-
methadone was applied. After 8h and 24h, D,L-methadone 
reduced the doxorubicin efflux strongly (Figure 4C) 
indicating that D,L-methadone increases doxorubicin 
uptake and inhibits doxorubicin efflux out of leukemia 
cells. This suggests that D,L-methadone as well as 
doxorubicin mutually increase their cytotoxic potential.
Apoptosis induction by D,L-methadone and 
doxorubicin depends on opioid receptor activation 
inducing cAMP downregulation 
To further analyze the role of opioid-receptor 
triggering in apoptosis induction and consequently 
activation of apoptotic pathways, the BCP-ALL cell line 
Tanoue was treated with D,L-methadone, doxorubicin 
or with the opioid-receptor antagonist naloxone alone 
or in different combinations with each other (Figure 
Figure 3: D,L-Methadone in combination with doxorubicin restores deficient activation of apoptotic pathways in 
BCP-ALL cells expressing moderate amounts of opioid receptors in vitro. (a) D,L-Methadone and doxorubicin co-treatment 
provokes caspase activation. The BCP-ALL cell line Tanoue was treated with different concentrations of D,L-methadone (as indicated) 
alone (- Doxo), with 0.06µg/mL doxorubicin (+ Doxo) alone or with D,L-methadone in addition to doxorubicin (+ Doxo). After 120h, 
Western blot analyses for caspase-9, caspase-3 and PARP were performed. The active fragment of caspase-9 was detected at ~37 kDa, the 
active fragment of caspase-3 at ~19 kDa and ~17 kDa and PARP cleavage at ~85 kDa. Equal protein loading was controlled by anti-β-actin 
antibody. (b) D,L-Methadone and doxorubicin-induced apoptosis depends on caspase activation. Pre-incubation of the cell line Tanoue 
with 50µM of the caspase inhibitor zVAD.fmk for 1h (white columns, + zVAD.fmk,) or without pre-treatment (black columns, - zVAD.
fmk,) was followed by addition of different concentrations of D,L-methadone (as indicated) in combination with 0.06µg/mL doxorubicin. 
Apoptosis induction was detected 120h after stimulation by FSC/SSC-analysis. The percentage of specific apoptosis was calculated as 
described in Figure 1B. Columns, mean of triplicates; bars, SD<10%. (c) Downregulation of XIAP and Bcl-xL by D,L-methadone and 
doxorubicin co-treatment. The cell line Tanoue was treated with different concentrations of D,L-methadone (as indicated) alone (- Doxo), 
with 0.06µg/mL doxorubicin (+ Doxo) alone or with D,L-methadone in addition to doxorubicin (+ Doxo). After 120h, Western blot 
analyses for XIAP and Bcl-xL were performed. XIAP was detected at ~58 kDa and Bcl-xL at ~30 kDa. Equal protein loading was controlled 
by anti-β-actin antibody.
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5A and 5B). After 96h, we found that blocking opioid-
receptors by naloxone strongly reduced the apoptotic 
rates of the combination treatment with D,L-methadone 
and doxorubicin (Figure 5A). Additionally, naloxone co-
treatment drastically reduced the activation of caspase-9 
and caspase-3 and cleavage of PARP (Figure 5B) 
indicating that opioid-receptor triggering is involved in 
apoptosis induction and in caspase activation.
Opioid receptor stimulation activates inhibitory 
Gi-proteins which in turn block adenylyl cyclase activity 
reducing cAMP (Figure 7) [18]. Pertussis toxin (PTX) 
inactivates Gi-proteins and blocks downregulation of 
cAMP (Figure 7) [34]. IBMX, however, increases cAMP 
levels as a result of phosphodiesterase inhibition (Figure 
7). To analyze the critical role of cAMP in opioid receptor 
activation-induced apoptosis, the BCP-ALL cell line 
Tanoue was treated with D,L-methadone, doxorubicin, and 
IBMX or PTX either alone or in different combinations 
with each other (Figure 5C and 5D). After 96h we found 
that upregulation of cAMP by IBMX (Figure 5C) as well 
as blocking downregulation of cAMP by PTX (Figure 
5D) strongly reduced the apoptotic rates of combination 
treatment with D,L-methadone and doxorubicin. In 
addition, the upregulation of cAMP by IBMX also 
decreased doxorubicin-induced apoptosis (Figure 5C). 
These results indicate that the activation of Gi-protein-
coupled opioid receptors is essential for the induction of 
apoptosis which might be regulated via the intracellular 
cAMP levels.
Inhibition of tumor growth in vivo 
In vitro results demonstrated that D,L-methadone 
induces apoptosis in several leukemia cell lines and 
increases the cytotoxicity of doxorubicin. To confirm 
the clinical relevance of the anti-cancer potential of D,L-
methadone alone or in combination with doxorubicin and 
to verify the results obtained so far an ALL-xenograft 
study was undertaken (Figure 6).
For the in vivo study, a patient-derived ALL-
xenograft model (ALL-SCID6) was used. Its phenotypic 
and genotypic identity with the original patient 
sample was proven [28]. The experiment started with 
subcutaneous inoculation of ALL-SCID6 fragments from 
an in vivo passage into male NOD/SCID/IL2rγ null (NSG) 
mice. After randomization, D,L-methadone was orally 
administered after ALL-inoculation with increasing doses. 
When tumors were palpable, doxorubicin treatment was 
initiated. D,L-Methadone and doxorubicin treatment led 
to a significant inhibition of tumor growth at comparable 
levels (Figure 6). Combination treatment with D,L-
Figure 4: Doxorubicin enhances opioid receptor expression whereas D,L-methadone enhances doxorubicin uptake 
and inhibits its efflux. (a) Doxorubicin enhances opioid receptor expression on the cells` surface. The BCP-ALL cell line Tanoue 
was treated for 96h with 0.06µg/mL doxorubicin. After staining of doxorubicin-treated (+ Doxo) and untreated cells (- Doxo) with 
naloxone-fluoresceine relative fluorescence intensities were determined flowcytometrically. X-fold increase in opioid receptor expression 
is shown after subtracting the cells autofluorescence (- Doxo) and doxorubicin fluorescence (+ Doxo). (b) D,L-methadone enhances 
doxorubicin uptake. The BCP-ALL cell line Tanoue was either pre-treated with 0.3µg/mL doxorubicin (black columns, Doxo) alone or 
with a combination of doxorubicin and 3µg/mL D,L-methadone (hatched columns, Doxo + D,L-Methadone) for 2h, 4h, 8h and 24h. Cell 
uptake was analyzed via doxorubicin fluorescence in cells using flow cytometry after 2h, 4h, 8h and 24h (maximum uptake). (C) D,L-
Methadone inhibits doxorubicin efflux. 24h after maximal uptake of doxorubicin (0h, maximum uptake) cells were washed with medium 
to remove doxorubicin. After washing doxorubicin-treated BCP-ALL cells, BCP-ALL cells were either left untreated (black columns, - 
D,L-Methadone) or treated with 3µg/mL D,L-methadone (hatched columns, + D,L-Methadone) and incubated for different points in time 
(8h, 24h). Doxorubicin efflux was analyzed via doxorubicin fluorescence in cells using flow cytometry after 8h and 24h. Values are mean 
fluorescence intensities +/-SE.
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methadone and doxorubicin had a similar anti-tumor 
efficacy as D,L-methadone or doxorubicin alone until day 
70 (Figure 6). At later time points, the tumor inhibition 
was longer lasting during the combined treatment of D,L-
methadone and doxorubicin (Figure 6). The therapy was 
well-tolerated with body weight changes of -10% for the 
combination and -8% or -4% for the D,L-methadone or 
doxorubicin treatment, respectively. To analyze D,L-
methadone serum concentrations in mice, 0.5h, 1h, 
4h and 24h after the last D,L-methadone application, 
serum was taken and D,L-methadone quantified by mass 
spectrometry. The serum concentrations of methadone 
were found between 56ng/mL and 230ng/mL in the time 
course of 0.5h until 4h after D,L-methadone application. 
The serum concentrations of doxorubicin were found 
between 156ng/mL and 198ng/mL. These results 
demonstrate that D,L-methadone and the co-treatment 
using doxorubicin and D,L-methadone significantly 
inhibited tumor growth in vivo.
DISCUSSION
ALL is a malignant disorder originating from 
single B- or T-lymphocyte progenitors [1]. Despite the 
significant progress made in the overall cure rate, the 
prognosis of relapsed ALL patients still remains poor [2] 
Figure 5: Combination treatment with D,L-Methadone and doxorubicin induced apoptosis depends on opioid-
receptor triggering via downregulation of cAMP. (a) Inhibition of opioid-receptor triggering inhibits apoptosis induction 
mediated by combination treatment with D,L-methadone and doxorubicin. The BCP-ALL cell line Tanoue was incubated with 60µg/mL 
naloxone (Naloxone), 3µg/mL D,L-methadone (D,L-Methadone) and 0.06µg/mL doxorubicin (Doxo) alone or in different combinations 
as indicated. After 96h, apoptotic cells were measured by FSC/SSC-analysis. (b) Inhibition of opioid-receptor triggering inhibits caspase 
activation mediated by combination treatment with D,L-methadone and doxorubicin. Tanoue cells were incubated with 60µg/mL naloxone 
(Naloxone), 3µg/mL D,L-methadone (D,L-Methadone) and 0.06µg/mL doxorubicin (Doxo) alone or in different combinations as indicated. 
Western blot analyses for caspase-9, caspase-3 and PARP were performed after 96h of incubation. The active fragment of caspase-9 was 
detected at ~37 kDa, of caspase-3 at ~19 kDa and ~17 kDa and PARP cleavage at ~85 kDa. Equal protein loading was controlled by anti-
β-actin antibody. (c) Increasing cAMP levels via repression of phosphodiesterase activity inhibits apoptosis. Tanoue cells were incubated 
for 96h with 200µM 3-isobutyl-1-methylxanthine (IBMX), 3µg/mL D,L-methadone (D,L-Methadone) and 0.06µg/mL doxorubicin (Doxo) 
alone or in different combinations as indicated. (d) Uncoupling Gi-proteins from opioid receptors inhibits apoptosis by preventing inhibition 
of adenylyl cyclases. Tanoue cells were incubated with 200ng/mL pertussis toxin (PTX), 3µg/mL D,L-methadone (D,L-Methadone) and 
0.06µg/mL doxorubicin (Doxo) alone or in different combinations as indicated. After 96h, the percentages of apoptotic cells were measured 
by FSC/SSC-analysis. The percentages of specific apoptosis was calculated as described in Figure 1B. Columns, mean of triplicates; bars, 
SD<10%. 
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as cellular resistances to anti-cancer drugs occur [3, 6, 7, 
35-37]. Hence, it is important to find alternate therapies 
overcoming resistances. Recent studies demonstrate that 
D,L-methadone kills leukemia cells in vitro and inhibits 
cell proliferation of lung cancer cells [22, 23, 25-27]. 
Additionally, D,L-methadone abrogates chemoresistance 
in leukemia cell lines without affecting normal 
lymphocytes [25]. Co-treatment with D,L-methadone and 
an anti-Bcl-2-agent leads to synergistic effects in leukemia 
cells [23]. However, the underlying mechanisms how D,L-
methadone leads to apoptosis induction are not understood. 
Additionally, the tumor growth inhibitory potential of D,L-
methadone has not been demonstrated in vivo nor have 
the synergistic effects in cell killing with conventionally 
administered chemotherapeutics been analyzed. In this 
study, we provide evidence that D,L-methadone induces 
apoptosis, activates caspases and increases doxorubicin-
triggered cell death in leukemia cells after opioid-receptor 
activation inducing the downregulation of cAMP. In 
addition, we demonstrate first that D,L-methadone can 
strongly reduce tumor growth of ALL in vivo.
Methadone binds as agonist to mu-opioid receptors. 
We found that D,L-methadone kills xenograft-derived 
ALL cells expressing high levels of opioid receptors. In 
contrast, D,L-methadone induces cell death only slightly 
in xenograft-derived ALL cells and cell lines expressing 
moderate opioid receptor amounts indicating that D,L-
methadone-induced apoptosis depends on critical levels 
of opioid receptor expression in leukemia cells.
Combination treatment may prove to be 
advantageous in malignancies that still partially respond 
to either treatment alone as different therapeutics are 
known to interact with each other amplifying weaker 
death signals [2, 5, 35, 38-43]. Combination treatment 
with D,L-methadone and doxorubicin enhances the anti-
tumor efficacy of both agents synergistically in BCP-
ALL cells expressing moderate levels of opioid-receptors 
and increases caspase activation playing a critical role 
in apoptosis induction in sensitive and resistant cancer 
cells [6]. Furthermore, the downregulation of the anti-
apoptotic proteins XIAP and Bcl-xL involved in the 
occurrence of resistances in many malignancies like ALL 
or NHL [44-48] is markedly enhanced. These suggest that 
combination treatment of D,L-methadone and doxorubicin 
increases apoptosis induction, caspase activation and 
downregulation of XIAP and Bcl-xL synergistically.
Resistance to conventional chemotherapeutic 
drugs is a limiting factor of therapies whereby multidrug 
resistances resulting from overexpression of drug 
transporters such as P-gp are well-characterized [33, 
49]. While in healthy cells the P-gp expression belongs 
to the normal cellular defense system, in cancer cells the 
overexpression of P-gp correlates with decreased survival 
and poor outcome [50, 51]. D,L-Methadone could be 
shown to be a substrate of P-gp [33, 49] inhibiting its 
action [30-32]. We found that co-treatment of doxorubicin 
with D,L-methadone enhances doxorubicin uptake and 
furthermore inhibits doxorubicin-efflux out of leukemia 
cells, suggesting that D,L-methadone sensitizes leukemia 
cells for doxorubicin-induced apoptosis by increasing 
concentrations of doxorubicin within the cells. 
Posovsky et al found that chemotherapeutic drugs 
like doxorubicin sensitize BCP-ALL cells expressing low 
amounts of CD95 receptors on their surface for CD95-
mediated apoptosis and caspase activation by upregulating 
CD95 receptors [29]. The enhanced toxicity of the 
combination treatment of D,L-methadone and doxorubicin 
is associated with an increased expression of opioid-
receptors after doxorubicin treatment. Therefore, D,L-
methadone can bind in higher amounts to cells co-treated 
with doxorubicin. These results indicate that the enhanced 
toxicity in the combination treatment with D,L-methadone 
and doxorubicin is associated with the upregulation of 
opioid-receptor expression mediated by doxorubicin and 
furthermore with an increased uptake and decreased efflux 
of doxorubicin mediated by D,L-methadone. 
Opioid receptors signal by catalyzing ligand-
dependent nucleotide exchange on Gi, thereby inhibiting 
adenylyl cyclase and modulating N-type calcium channels 
as well as G-protein–gated inwardly rectifying potassium 
(GIRK) channels leading to changes in cell signaling 
(Figure 7) [52]. The dependence of apoptosis induction 
on opioid-receptor triggering is underlined by their 
inhibition. Blocking opioid-receptor signaling with the 
Figure 6: Opioid receptor activation by D,L-
methadone inhibits growth of leukemia xenografts 
and increases doxorubicin sensitivity in vivo. Fragments 
of an in vivo passage of a patient-derived T-ALL (ALL-SCID6, 
see also Figure 1) were transplanted into male NSG mice. 
Mice were treated with D,L-methadone alone (n=8, orally day 
1-76, D,L-Methadone), with doxorubicin alone (n=8, i.v. day 
46,53,60,76, Doxorubicin) or with a combination treatment 
with D,L-methadone and doxorubicin (n=8, D,L-Methadone + 
Doxorubicin). D,L-Methadone was used in weekly increasing 
doses from 20 up to 120mg/kg/day and doxorubicin in a dose 
of 3mg/kg. As control group xenografted mice were treated i.v. 
with 10% Tween 80 in saline (n=8, Vehicle). For 76 days after 
transplantation all mice were monitored for tumor growth, body 
weight and health condition. *significant to vehicle (p<0.05, 
Mann-Whitney U test). 
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opioid receptor antagonist naloxone inhibited combination 
treatment with D,L-methadone and doxorubicin-induced 
apoptosis and caspase activation in a high rate, suggesting 
that opioid-receptor triggering by D,L-methadone is 
involved in apoptosis induction and caspase activation 
(Figure 7). Maneckjee et al showed for human lung 
cancer cells that the opioid receptor antagonist naloxone 
in combination with methadone increased cAMP levels 
suggesting that inhibition of opioid receptor activation 
by methadone rises cAMP [26]. The second messenger 
cAMP is involved in a number of physiologic functions 
in response to various extracellular stimuli controlling 
cell proliferation, differentiation, and apoptosis whereby 
it can either inhibit or stimulate apoptosis dependent on 
the respective cell type [20, 53]. For various tumor cells 
like pancreatic or leukemia cells stimulated with different 
agents, it could be demonstrated that cAMP elevation is 
associated with impaired cell death [54-56]. Responsible 
for this protective action of cAMP against apoptosis is 
among others the synthesis of anti-apoptotic proteins, 
inactivation of pro-apoptotic proteins, and activation of 
PI3K-dependent Akt [57-59]. In the AML cell line HL-
60, for instance, PKA inhibitors impair the cytoprotective 
effect from cAMP on the cells [60]. Activation of cAMP 
plays also a critical role in inhibiting DNA-damage- and 
doxorubicin-induced apoptosis via p53 dephosphorylation 
[15, 16] and furthermore by NF-κB activation [61]. Opioid 
receptor stimulation activates inhibitory Gi-proteins 
which in turn block adenylyl cyclase activity reducing 
cAMP [17]. We found that D,L-methadone induced 
apoptosis and activated caspases by triggering opioid 
receptors via downregulation of cAMP. Blocking the 
activation of opioid receptors by naloxone or inhibiting Gi-
proteins with PTX increased cAMP and strongly reduced 
apoptotic signaling triggered by the co-treatment with 
D,L-methadone and doxorubicin. In addition, upregulation 
of cAMP by inhibition of cAMP phosphodiesterases 
using IBMX reduced the cytoxicity of the combination 
treatment using D,L-methadone and doxorubicin in human 
BCP-ALL cells. Furthermore, opioid receptor triggering 
by D,L-methadone inhibits proliferation and leads to 
accumulation of leukemia cells in G1-phase which was 
previously observed [25]. These results suggest that 
opioid receptor activation by D,L-methadone triggers 
downregulation of cAMP mediating caspase activation 
and apoptosis induction in leukemia cells (Figure 7) and 
sensitizes leukemia cells for doxorubicin treatment.
In vitro results have shown that D,L-methadone can 
induce apoptosis in several leukemia cell lines [23, 25]. In 
the current study, we could verify the clinical relevance 
with patient-derived ALL cells ex vivo and we provide 
the first evidence that D,L-methadone as monotherapy or 
in combination with doxorubicin leads to a strong tumor 
growth inhibition in a patient-derived leukemia model 
in vivo. Both the anti-leukemic efficacy and the side 
effects of D,L-methadone alone or in combination with 
doxorubicin were comparable with those of doxorubicin 
alone. Anyhow, a longer lasting growth inhibition could 
be proven upon combination treatment. The serum 
concentrations of methadone in mice correlated with 
Figure 7: Opioid receptor signaling. Stimulation of opioid receptors (OR) by agonists like D,L-methadone leads to an activation 
of the inhibitory Gi-protein. The alphai-subunit inactivates adenylyl cyclases (AC) resulting in a reduction of cAMP levels within the cell 
which in turn leads to apoptosis. Naloxone as opioid receptor antagonist inhibits competitively opioid receptors. PTX (pertussis toxin) 
inactivates Gi-proteins and blocks downregulation of cAMP. IBMX (3-isobutyl-1-methylxanthine) inhibits phosphodiesterase activity 
(PDE) and increases cAMP levels.
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the concentrations showing in vitro cytotoxicity. This 
indicates that D,L-methadone may have a promising 
therapeutic potential in leukemia therapy and could 
improve therapeutic success of conventional therapies.
Taken together, our results demonstrate that 
D,L-methadone induces apoptosis, mediates caspase 
activation and sensitizes leukemia cells for doxorubicin 
treatment through opioid receptor activation triggering 
the downregulation of cAMP (Figure 7). D,L-methadone-
induced cell death depends on critical levels of 
opioid receptor expression which can be increased by 
doxorubicin. Additionally, D,L-methadone increases 
doxorubicin influx and hampers its efflux in leukemia 
cells. Furthermore, we could demonstrate for the first 
time that D,L-methadone alone or in combination with 
doxorubicin leads to a significant tumor growth inhibition 
in a patient-derived leukemia model in vivo. These results 
have important implications for the development of novel 
strategies in cancer therapy especially when conventional 
therapies are less effective.
METHODS
Drugs and reagents
For the in vitro experiments, D,L-methadone 
hydrochloride (D,L-methadone) and doxorubicin were 
purchased from Sigma (Taufkirchen, Germany), naloxone 
from Fagron GmbH&Co. KG (Barsbüttel, Germany), and 
pertussis toxin (PTX) from Calbiochem (Nottingham, 
UK). Prior to each experiment these substances were 
freshly dissolved in sterile distilled water to ensure 
the constant quality of the preparations. 3-Isobutyl-1-
methylxanthine (IBMX, Sigma) was freshly dissolved in 
0.01N NaOH.
For in vivo application, we used D,L-methadone 
(Methaddict, Hexal, Germany) as 5mg tablets purchased 
from the local pharmacy. The tablets were pulverized 
and solubilized freshly before use in 10% Tween 80 in 
saline. Doxorubicin (Hexal) was purchased as injection 
solution (5mg/mL) and diluted freshly with saline to the 
appropriate concentrations.
Cell lines
The human B-cell leukemia (BCP-ALL) cell lines 
Tanoue, Reh and Nalm6 were obtained from the DSMZ 
(Braunschweig, Germany) and cultured in RPMI 1640 
(Invitrogen) containing 10% FCS (Lonza, Verviers, 
Belgium), 1mmol/L glutamine (Invitrogen), 1% penicillin/
streptomycin (Invitrogen), 25mmol/L HEPES (Biochrom) 
at 37°C, 95% air/ 5% CO2. In experimental settings, the 
leukemia cells were seeded in a density of 100000 cells/
mL.
Serum concentrations of methadone
Determination of methadone in serum samples was 
carried out after liquid/liquid extraction using a mass 
spectrometer equipped with a gas chromatograph (GC/
MS). As internal standard d9-methadone was added. The 
mass selective detector was operated in electron impact 
mode. Data were acquired in the selected-ion monitoring 
mode. The analytes were identified with the following 
masses m/z 294, 223, 72 (target ion) for methadone and 
m/z 303, 226, and 78 for d9-methadone with a limit of 
detection of 0.8ng/mL and a limit of quantification of 
1.2ng/mL.
Serum concentrations of doxorubicin 
Determination of doxorubicin and its main 
metabolites in serum were performed as described 
previously [62, 63]. Using this validated method, the 
quantification of doxorubicin, doxorubicinol, and 7-deoxy-
doxorubicinolon was possible with a LLQ of 0.2ng/mL. 
Patient-derived ALL xenografts
For in vivo use the ALL-SCID6 model was 
chosen. Fragments from in vivo passaged tumors were 
transplanted subcutaneously at day 0 to 32 male NOD/
SCID/IL2rγ null (NSG) mice. After randomization oral 
treatment (by gavage) with D,L-methadone was initiated 
one day later and performed daily until the end of the 
experiment with increasing doses: 1stweek 20mg/kg/d, 
2ndweek 30mg/kg/d, 3rdweek 40mg/kg/d, 4thweek 60mg/
kg/d, 5th-10thweek 2x60mg/kg/inj. The dose adaptation was 
necessary to avoid toxic deaths because of an overdosage 
of D,L-methadone. The maximum tolerated dose of D,L-
methadone in the employed mouse strain is 2x60mg/kg/
inj. At day 46, 53, 60 and 76 doxorubicin (3mg/kg) was 
administered i.v. Tumor size was measured twice weekly 
at two dimensions and tumor volumes were calculated 
according to the formula (length x width2)/2. Mean tumor 
volumes and standard deviations were calculated per 
group. Treated to control values (T/C) in percent were 
calculated by relating mean tumor volumes of each group 
at each measurement day to the controls. Individual body 
weight was determined twice per week as parameter for 
tolerability. Body weight changes [%] were calculated 
by relating the mean values of each group to the first 
measurement day.
Serum from D,L-methadone treated mice was taken 
0.5, 1, 4 and 24 hours after last D,L-methadone treatment 
at day 76, respectively, and stored at -20°C until the 
determination of methadone concentration. Mice were 
sacrificed at day 77 for ethical reasons. 
For the in vitro investigations, cell suspensions 
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of human xenograft-derived ALL cells from patients 
with T-cell (ALL-SCID6, ALL-SCID3), B-cell (ALL-
SCID7) and B-cell precursor (BCP, pre-B-ALL-SCID) 
acute leukemia were gained and cultivated in vitro and 
were phenotypically and genotypically characterized as 
described [28]. All animal experiments were approved 
by the local responsible authorities (LaGeSo Berlin) and 
performed according to the guidelines for animal welfare 
in oncological experiments [64].
Flow cytometric assay for determination of cell 
surface opioid-receptors
Cells were washed in PBS supplemented with 
1% FCS, centrifuged and resuspended in PBS/1% FCS 
containing naloxone-fluoresceine (0.05mM, Invitrogen) 
[65]. After 30min of incubation at RT, the cells were 
washed, centrifuged and resuspended in icecold PBS/1% 
FCS. Flow cytometry analysis was performed using 
FACSCalibur (BD, Heidelberg, Germany).
Induction of apoptosis and determination of cell 
survival
ALL cells were treated with D,L-methadone (≤ 3µg/
mL therapeutic plasma concentration) alone or in addition 
to doxorubicin in 175cm2 flasks or 96-well plates. Further 
experiments were performed simultaneously after addition 
of 60µg/mL naloxone, 200µM IBMX (3-isobutyl-1-
methylxanthine) or 200ng/mL PTX (pertussis toxin). After 
different points in time, apoptosis rates were measured 
by flow cytometry [66, 67]. To determine apoptosis, 
cells were lysed with Nicoletti-buffer containing sodium 
citrate (0.1%), Triton X 100 (0.1%) and propidium iodide 
(50µg/mL) as described by Nicoletti [67]. Apoptotic 
cells were determined by hypodiploid DNA (subG1) or 
forward scatter/side scatter analysis [66]. Cell survival was 
determined by forward scatter/side scatter analysis using 
flow cytometry [66]. The percentage of specific apoptosis 
was calculated as follows: 100 x [experimental dead cells 
(%) - spontaneous dead cells in medium (%)] / [100% 
-spontaneous dead cells in medium (%)]. The spontaneous 
dead cells were in the range of 5 to 10% using cell lines. 
The spontaneous dead of untreated human xenograft-
derived ALL cells was less than 35% at 24h and 48h.
General caspase inhibition by zVAD.fmk
For inhibition of apoptosis, leukemia cells were 
treated with the pancaspase inhibitor zVAD.fmk (z-Val-
Ala-D,L-Asp-fluoromethylketone; Bachem, Bubendorf, 
Germany) as described [68, 69]. 50µM zVAD.fmk 
was added to the cells 1h before stimulation with D,L-
methadone and doxorubicin. The percentage of apoptotic 
cells was determined by FSC/SSC analysis via flow 
cytometry [66].
Western blot analysis
Western blot analyses were performed as described 
[37, 68-70]. Whole cell lysates were immunodetected for 
PARP, caspase-3, caspase-9, XIAP, Bcl-xL and ß-actin 
using rabbit-anti-PARP-polyclonal-antibody (1:5000, 
Roche), anti-XIAP-monoclonal-antibody (both 1:1000, 
BD Transduction Laboratories, Heidelberg, Germany), 
mouse-anti-caspase-3-monoclonal-antibody, rabbit-
anti-caspase-9-polyclonal-antibody (both 1:1000, Cell 
Signaling, Boston, MA, USA) rabbit-anti-Bcl-xL-
polyclonal-antibody (1:1000, Santa-Cruz, Heidelberg, 
Germany) and mouse-anti-ß-actin-monoclonal-antibody 
(1:5000, Sigma). As secondary antibodies peroxidase-
conjugated-goat-anti-mouse IgG or peroxidase-
conjugated-goat-anti-rabbit IgG (1:5000, Santa-Cruz) 
were used for the enhanced chemoluminescence system 
(ECL, Amersham-Pharmacia, Freiburg, Germany). Equal 
protein loading was controlled by ß-actin detection.
Analysis of doxorubicin uptake and efflux
For analysis of doxorubicin uptake, the BCP-
leukemia cell line Tanoue was seeded in a density of 
100000 cells/mL in 175cm2 flasks and was either left 
untreated or incubated with 0.3µg/mL doxorubicin or a 
combination of 0.3µg/mL doxorubicin and 3µg/mL D,L-
methadone. After different time point in time cells were 
washed and the relative doxorubicin uptake in cells was 
analyzed using flow cytometry.
For analysis of doxorubicin efflux, cells were 
washed to remove doxorubicin from medium after 
incubation for 24h (maximum uptake). Next, cells were 
incubated with fresh medium without doxorubicin or 
fresh medium containing 3µg/mL D,L-methadone without 
doxorubicin to measure doxorubicin efflux. After different 
time points, cells were harvested, washed and relative 
doxorubicin content in leukemia cells was analyzed using 
flow cytometry.
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